Clinical Trial Update: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing datopotamab deruxtecan (Dato-DXd) versus investigator's choice chemotherapy in locally recurrent or metastatic triple-negative br…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (investigator's choice)
• Dato-DXd (datopotamab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING